systhiperСистемные гипертензииSystemic Hypertension2075-082X2542-2189LLC «ИнтерМедсервис»systhiper-350Research ArticleМЕТАБОЛИЧЕСКИЕ НАРУШЕНИЯMETABOLIC DISTURBANCESЭффективность и безопасность Мертенила (розувастатина) 40 мг/сут у пациентов с семейной гиперхолестеринемиейEfficacy and safety of Mertenil (rosuvastatin) 40 mg in patients with familial hypercholesterolemiaЗубареваМ. Ю.ZubarevaM. Yu.mzubareva06@mail.ruМалышевП. П.MalyshevP. P.ppmal@rambler.ruРожковаТ. А.RozhkovaT. A.noemail@neicon.ruКухарчукВ. В.KuharchukV. V.noemail@neicon.ruИКК им. А.Л.Мясникова ФГБУ РКНПК Минздрава России, МоскваRussian Federation2014231220221124247Copyright © Зубарева М.Ю., Малышев П.П., Рожкова Т.А., Кухарчук В.В., 20222022Зубарева М.Ю., Малышев П.П., Рожкова Т.А., Кухарчук В.В.Zubareva M.Y., Malyshev P.P., Rozhkova T.A., Kuharchuk V.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.syst-hypertension.ru/jour/article/view/350

Семейная гиперхолестеринемия (СХГС) - это заболевание, обусловленное генетическими нарушениями, приводящими к значительному повышению концентрации холестерина (ХС) в крови и, как следствие, - к повышенному риску раннего развития ишемической болезни сердца. Розувастатин является наиболее мощным гиполипидемическим препаратом из группы ингибиторов ГМГ-КоА редуктазы, разрешенным к клиническому применению в Российской Федерации.Цель нашего исследования - изучить эффективность, безопасность и переносимость терапии Мертенилом (розувастатин) в максимальной дозе 40 мг/сут у пациентов с СХГС.Материалы и методы. Исследование было проспективным открытым, длительностью 16 нед. В исследование были включены 40 пациентов, мужчин и женщин в возрасте от 18 и старше, с фенотипическим диагнозом СГХС. У 18 пациентов была обнаружена мутация Arg35000Gln гена APOB100. Мужчины составляли 40% общего числа пациентов. Средний возраст больных был 55,9 года, средний уровень ХС липопротеинов низкой плотности (ЛПНП) - 7,2 (1,2) ммоль/л. Пациенты не принимали статины до включения в исследование (в течение не менее чем 3 мес).Результаты. Монотерапия розувастатином 40 мг/сут в течение 16 нед исследования способствовала снижению уровня ХС ЛПНП на 55,1% (р<0,001) и уровня ApoВ-100 на 45,1% (р<0,001), снижение уровня триглицеридов составило -20,1% (р<0,01). Показатели активности аспартатаминотрансферазы, аланинаминотрансферазы и креатинкиназы через 16 нед терапии достоверно не отличались от исходных значений и не превышали 1,5 верхнего предела нормы. Через 16 нед терапии было выявлено снижение уровня высокочувствительного С-реактивного белка и мочевой кислоты от исходного (р<0,05). В течение всего периода терапии побочных явлений отмечено не было.Заключение. Терапия Мертенилом (розувастатин) 40 мг/сут является доступным и эффективным методом лечения гетерозиготной СГХС.

Familial hypercholesterolemia (FH) is an inherited disease that results in high levels of total cholesterol, causing the risk of early ischemic heart disease (IHD). Rosuvastatin is the high-potency hypolipidemic agent of HMG-CoA reductase inhibitors which is approved for clinical use.The goal of our research is to study efficacy, safety Mertenil (rosuvastatin) acceptability of maximal course dose of 40 mg in patients with phenotypic FH. Materials and methods. The 16-week open study was prospective. The study included 40 men and women at the age of 18 years and older with phenotypic FH. 18 patients had the Arg3500Gln mutation in APOB100 gene. Men accounted for 40% of total number of patients. The average age of patients was 55,9 years and average LDL cholesterol (LDL-c) level was 7,2 (1,2) mmol/l. Patients did not accept statins before the inclusion in this study (for a period no less than 3 months).Results. Rosuvastatin40 mg monotherapy 16 weeks study contributed to decrease LDL-c by 50% (p<0,001) and ApoB-100 by 45,1% (p<0,001), TG by 20,1% (p<0,01). Aspartate aminotransferase, alanintransferase and creatinekinase activity were not statistically significant from the base values and were not exceed 1,5 superior normal limit after 16-weeks study. Through 16 weeks of therapy the identified reduction of hsCRP and uric acid were observed (p<0,05). Side-effects were not observed throughout the period of treatment.Conclusion. Therapy of Mertenil (rosuvastatin) 40 mgis available and effective in treatment of heterozygous FH.

семейная гиперхолестеринемиярозувастатинМертенилтерапияfamilial hypercholesterolemiarosuvastatinMertenilpharmacotherapyReferencesWiesbauer F, Blessberger H, Azar D et al. Familial - combined hyperlipidaemia in very young myocardial infarction survivors. Eur Heart J 2009; 30: 1073-9.Wiesbauer F, Blessberger H, Azar D et al. Familial - combined hyperlipidaemia in very young myocardial infarction survivors. Eur Heart J 2009; 30: 1073-9.Wierzbicki A.S, Humphries S.E, Minhas R on behalf of the Guideline Development G. Familial hypercholesterolaemia: summary of NICE guidance. BMJ 2008; 337: a1095.Wierzbicki A.S, Humphries S.E, Minhas R on behalf of the Guideline Development G. Familial hypercholesterolaemia: summary of NICE guidance. BMJ 2008; 337: a1095.Малышев П.П., Рожкова Т.А., Соловьева Е.Ю. и др. Развитие ишемической болезни сердца при гетерозиготной форме семейной гиперхолестеринемии. Кардиоваск. терапия и профилактика. 2006; 5 (5): 5-13.Малышев П.П., Рожкова Т.А., Соловьева Е.Ю. и др. Развитие ишемической болезни сердца при гетерозиготной форме семейной гиперхолестеринемии. Кардиоваск. терапия и профилактика. 2006; 5 (5): 5-13.Кухарчук В.В., Малышев П.П., Мешков А.Н. Семейная гиперхолестеринемия в России: генетическая и фенотипическая характеристика. Терапевт. арх. 2009; 9: 23-8.Кухарчук В.В., Малышев П.П., Мешков А.Н. Семейная гиперхолестеринемия в России: генетическая и фенотипическая характеристика. Терапевт. арх. 2009; 9: 23-8.Civeira F. International Panel on Management of Familial Hypercholesterolemia. Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia. Atherosclerosis 2004; 173:55-68.Civeira F. International Panel on Management of Familial Hypercholesterolemia. Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia. Atherosclerosis 2004; 173:55-68.Hopkins P.N, Toth P.P, Ballantyne C.M, Rader D.J. National Lipid Association Expert Panel on Familial Hypercholesterolemia. Familial hypercholesterolemias: prevalence, genetics, diagnosis and screening recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol 2011; 5: S9-17.Hopkins P.N, Toth P.P, Ballantyne C.M, Rader D.J. National Lipid Association Expert Panel on Familial Hypercholesterolemia. Familial hypercholesterolemias: prevalence, genetics, diagnosis and screening recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol 2011; 5: S9-17.Watts G.F, Sullivan D.R, van Bockxmeer F.M et al. A model of care for familial hypercholesterolaemia: key role for clinical biochemistry. Clin Biochem Rev 2012; 33: 25-31.Watts G.F, Sullivan D.R, van Bockxmeer F.M et al. A model of care for familial hypercholesterolaemia: key role for clinical biochemistry. Clin Biochem Rev 2012; 33: 25-31.Nordestgaard B.G, Chapman M.J, Humphries S.E et al. European Atherosclerosis Society Consensus Panel. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease. Eur Heart J 2013; 34: 3478-90.Nordestgaard B.G, Chapman M.J, Humphries S.E et al. European Atherosclerosis Society Consensus Panel. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease. Eur Heart J 2013; 34: 3478-90.Национальное общество по изучению атеросклероза (НОА). Российское кардиологическое общество (РКО). Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Российские рекомендации,V пересмотр. М., 2012.Национальное общество по изучению атеросклероза (НОА). Российское кардиологическое общество (РКО). Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Российские рекомендации,V пересмотр. М., 2012.Smilde T.J, Wissen S, Wollersheim H et al. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double - blind trial. Lancet 2001; 357: 577-81.Smilde T.J, Wissen S, Wollersheim H et al. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double - blind trial. Lancet 2001; 357: 577-81.Jongh S, Ose L, Szamosi T et al. Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized, double - blind, placebo - controlled trial with simvastatin. Circulation 2002; 106: 2231-7.Jongh S, Ose L, Szamosi T et al. Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized, double - blind, placebo - controlled trial with simvastatin. Circulation 2002; 106: 2231-7.Avis H.J, Hutten B.A, Gagne C et al. Efficacy and safety of rosuvastatin therapy for children with familial hypercholesterolemia. J Am Coll Cardiol 2010; 55: 1121-6.Avis H.J, Hutten B.A, Gagne C et al. Efficacy and safety of rosuvastatin therapy for children with familial hypercholesterolemia. J Am Coll Cardiol 2010; 55: 1121-6.Avis H.J, Vissers M.N, Stein E.A et al. A systematic review and meta - analysis of statin therapy in children with familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 2007; 27: 1803-10.Avis H.J, Vissers M.N, Stein E.A et al. A systematic review and meta - analysis of statin therapy in children with familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 2007; 27: 1803-10.Versmissen J, Oosterveer D.M, Yazdanpanah M et al. Efficacy of statins in familial hypercholesterolaemia: a long term cohort study. BMJ 2008; 337: a2423.Versmissen J, Oosterveer D.M, Yazdanpanah M et al. Efficacy of statins in familial hypercholesterolaemia: a long term cohort study. BMJ 2008; 337: a2423.Neil A, Cooper J, Betteridge J et al. Reductions in all - cause, cancer, and coronary mortality in statin - treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study. Eur Heart J 2008; 29: 2625-33.Neil A, Cooper J, Betteridge J et al. Reductions in all - cause, cancer, and coronary mortality in statin - treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study. Eur Heart J 2008; 29: 2625-33.Kastelein J.J, Akdim F, Stroes E.S et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 2008; 358: 1431-43.Kastelein J.J, Akdim F, Stroes E.S et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 2008; 358: 1431-43.Scientific Steering Committee on behalf of the Simon Broome Register Group. Mortality in treated heterozygous familial hypercholesterolaemia: implications for clinical management. Atherosclerosis 1999; 142: 105-12.Scientific Steering Committee on behalf of the Simon Broome Register Group. Mortality in treated heterozygous familial hypercholesterolaemia: implications for clinical management. Atherosclerosis 1999; 142: 105-12.Mohrschladt M.F, Westendorp R.G, Gevers Leuven J.A, Smelt A.H. Cardiovascular disease and mortality in statin - treated patients with familial hypercholesterolemia. Atherosclerosis 2004; 172: 329-35.Mohrschladt M.F, Westendorp R.G, Gevers Leuven J.A, Smelt A.H. Cardiovascular disease and mortality in statin - treated patients with familial hypercholesterolemia. Atherosclerosis 2004; 172: 329-35.Neil H.A, Hammond T, Mant D, Humphries S.E. Effect of statin treatment for familial hypercholesterolaemia on life insurance: results of consecutive surveys in 1990 and 2002. BMJ 2004; 328: 500-1.Neil H.A, Hammond T, Mant D, Humphries S.E. Effect of statin treatment for familial hypercholesterolaemia on life insurance: results of consecutive surveys in 1990 and 2002. BMJ 2004; 328: 500-1.Fabbri G, Maggioni A. Cardiovascular risk reduction: what do recent trials with rosuvastatin tell us? Adv Ther 2009; 26 (5): 469-87.Fabbri G, Maggioni A. Cardiovascular risk reduction: what do recent trials with rosuvastatin tell us? Adv Ther 2009; 26 (5): 469-87.Williams R.R, Hunt S.C, Schumacher M.C et al. Diagnosing heterozygous familial hypercholesterolemia using new practical criteria validated by molecular genetics. Am J Cardiol 1993; 72: 171-6.Williams R.R, Hunt S.C, Schumacher M.C et al. Diagnosing heterozygous familial hypercholesterolemia using new practical criteria validated by molecular genetics. Am J Cardiol 1993; 72: 171-6.Innerarity T.L, Mahley R.W, Weisgraber K.H et al. Familial defective apolipoprotein B-100: a mutation of apolipoprotein B that causes hypercholesterolemia. J Lipid Res 1990; 31: 1337-49.Innerarity T.L, Mahley R.W, Weisgraber K.H et al. Familial defective apolipoprotein B-100: a mutation of apolipoprotein B that causes hypercholesterolemia. J Lipid Res 1990; 31: 1337-49.Whitfield A.J, Barrett P.H, van Bockxmeer F.M, Burnett J.R. Lipid disorders and mutations in the APOB gene. Clin Chem 2004; 50: 1725-32.Whitfield A.J, Barrett P.H, van Bockxmeer F.M, Burnett J.R. Lipid disorders and mutations in the APOB gene. Clin Chem 2004; 50: 1725-32.Ejarque I, Real J.T, Martinez-Hervas S et al. Evaluation of clinical diagnosis criteria of familial ligand defective apoB 100 and lipoprotein phenotype comparison between LDL receptor gene mutations affecting ligand - binding domain and the R3500Q mutation of the apoB gene in patients from a South European population. Transl Res 2008; 151: 162-7.Ejarque I, Real J.T, Martinez-Hervas S et al. Evaluation of clinical diagnosis criteria of familial ligand defective apoB 100 and lipoprotein phenotype comparison between LDL receptor gene mutations affecting ligand - binding domain and the R3500Q mutation of the apoB gene in patients from a South European population. Transl Res 2008; 151: 162-7.Малышев П.П., Мешков А.Н., Котова Л.А., Кухарчук В.В.Семейный дефект аполипопротеина В-100: молекулярная основа заболевания и клинико - биохимические особенности пациентов. Кардиоваск. терапия и профилактика. 2007; 6 (6):40-5.Малышев П.П., Мешков А.Н., Котова Л.А., Кухарчук В.В.Семейный дефект аполипопротеина В-100: молекулярная основа заболевания и клинико - биохимические особенности пациентов. Кардиоваск. терапия и профилактика. 2007; 6 (6):40-5.Myant N.B. Familial defective apolipoprotein B-100: a review, including some comparisons with familial hypercholesterolaemia. Atherosclerosis 1993; 104: 1-18.Myant N.B. Familial defective apolipoprotein B-100: a review, including some comparisons with familial hypercholesterolaemia. Atherosclerosis 1993; 104: 1-18.Pitt B, Loscalzo J, Monyak J et al. Comparison of lipid - modifying efficacy of rosuvastatin versus atorvastatin in patients with acute coronary syndrome (from the LUNAR study). Am J Cardiol 2012; 109 (9): 1239-46.Pitt B, Loscalzo J, Monyak J et al. Comparison of lipid - modifying efficacy of rosuvastatin versus atorvastatin in patients with acute coronary syndrome (from the LUNAR study). Am J Cardiol 2012; 109 (9): 1239-46.Leiter L.A, Rosenson R.S, Stein E et al. POLARIS study investigators. Efficacy and safety of rosuvastatin 40 mg versus atorvastatin 80 mg in high - risk patients with hypercholesterolemia: results of the POLARIS study. Atherosclerosis 2007; 194 (2): e154-64.Leiter L.A, Rosenson R.S, Stein E et al. POLARIS study investigators. Efficacy and safety of rosuvastatin 40 mg versus atorvastatin 80 mg in high - risk patients with hypercholesterolemia: results of the POLARIS study. Atherosclerosis 2007; 194 (2): e154-64.CRESTOR: Product monograph. http://www.cma.ca/crestor_product%20monographpdf.pdf.CRESTOR: Product monograph. http://www.cma.ca/crestor_product%20monographpdf.pdf.Ridker P.M, Danielson E, Fonseca F.A.H et al for the JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359: 2195-207.Ridker P.M, Danielson E, Fonseca F.A.H et al for the JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359: 2195-207.Betteridge D.J, Gibson M. Effect of rosuvastatin on LDL-C and CRP levels in patients with type 2 diabetes: results of ANDROMEDA study. Atheroscler (Suppl.) 2004; 5: 107-8.Betteridge D.J, Gibson M. Effect of rosuvastatin on LDL-C and CRP levels in patients with type 2 diabetes: results of ANDROMEDA study. Atheroscler (Suppl.) 2004; 5: 107-8.Alderman M.H. Serum Uric Acid As a Cardiovascular Risk Factor for Heart Disease. Curr Hypertens Rep 2001; 3: 184-9.Alderman M.H. Serum Uric Acid As a Cardiovascular Risk Factor for Heart Disease. Curr Hypertens Rep 2001; 3: 184-9.Goldberg A.C, Hopkins P.N, Toth P.P et al. Familial Hypercholesterolemia: Screening, Diagnosis and Management of Pediatric and Adult Patients. Clinical Guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol 2011; 5 (35): S1-S8.Goldberg A.C, Hopkins P.N, Toth P.P et al. Familial Hypercholesterolemia: Screening, Diagnosis and Management of Pediatric and Adult Patients. Clinical Guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol 2011; 5 (35): S1-S8.Cholesterol Treatment Trialists’ (CTT) Collaborators. Efficacy and safety of cholesterol - lowering treatment: prospective meta - analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267-78.Cholesterol Treatment Trialists’ (CTT) Collaborators. Efficacy and safety of cholesterol - lowering treatment: prospective meta - analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267-78.Cholesterol Treatment Trialists Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta - analysis of data from 170 000 participants in 26 randomised trials. Lancet 2010; 376:1670-81.Cholesterol Treatment Trialists Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta - analysis of data from 170 000 participants in 26 randomised trials. Lancet 2010; 376:1670-81.

The authors declare that there are no conflicts of interest present.